The type III TGF-β receptor betaglycan transmembrane-cytoplasmic domain fragment is stable after ectodomain cleavage and is a substrate of the intramembrane protease β-secretase

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 2, 2011, Pages 332-339

  Blair, Cheyne R ^a   Stone, Jacqueline B ^a   Wells, Rebecca G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Secretase; Betaglycan; Ectodomain shedding; Regulated intramembrane proteolysis; TGF

Indexed keywords

GAMMA SECRETASE; PROTEOGLYCAN; SERINE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

ANIMAL CELL; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOPLASM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CRICETULUS; CYTOPLASM; ENZYME INHIBITORS; HEP G2 CELLS; HUMANS; HYDROXAMIC ACIDS; LUCIFERASES; MICE; NIH 3T3 CELLS; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 78650964786     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2010.12.005     Document Type: Article

References (77)

1. Andres J.L., DeFalcis D., Noda M., Massague J. Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J. Biol. Chem. 1992, 267:5927-5930.
2. Henis Y.I., Moustakas A., Lin H.Y., Lodish H.F. The types II and III transforming growth factor-beta receptors form homo-oligomers. J. Cell Biol. 1994, 126:139-154.
3. Lopez-Casillas F., Cheifetz S., Doody J., Andres J.L., Lane W.S., Massague J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 1991, 67:785-795.
4. Lopez-Casillas F., Wrana J.L., Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993, 73:1435-1444.
5. Moustakas A., Lin H.Y., Henis Y.I., Plamondon J., O'Connor-McCourt M.D., Lodish H.F. The transforming growth factor beta receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand. J. Biol. Chem. 1993, 268:22215-22218.
6. Wang X.F., Lin H.Y., Ng-Eaton E., Downward J., Lodish H.F., Weinberg R.A. Expression cloning and characterization of the TGF-beta type III receptor. Cell 1991, 67:797-805.
7. Brown C.B., Boyer A.S., Runyan R.B., Barnett J.V. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science 1999, 283:2080-2082.
8. Compton L.A., Potash D.A., Brown C.B., Barnett J.V. Coronary vessel development is dependent on the type III transforming growth factor beta receptor. Circ. Res. 2007, 101:784-791.
9. Droguett R., Cabello-Verrugio C., Riquelme C., Brandan E. Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol. 2006, 25:332-341.
10. Lopez-Casillas F., Riquelme C., Perez-Kato Y., Ponce-Castaneda M.V., Osses N., Esparza-Lopez J., Gonzalez-Nunez G., Cabello-Verrugio C., Mendoza V., Troncoso V., Brandan E. Betaglycan expression is transcriptionally up-regulated during skeletal muscle differentiation. Cloning of murine betaglycan gene promoter and its modulation by MyoD, retinoic acid, and transforming growth factor-beta. J. Biol. Chem. 2003, 278:382-390.
11. Sarraj M.A., Chua H.K., Umbers A., Loveland K.L., Findlay J.K., Stenvers K.L. Differential expression of TGFBR3 (betaglycan) in mouse ovary and testis during gonadogenesis. Growth Factors 2007, 25:334-345.
12. Stenvers K.L., Tursky M.L., Harder K.W., Kountouri N., Amatayakul-Chantler S., Grail D., Small C., Weinberg R.A., Sizeland A.M., Zhu H.J. Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol. Cell. Biol. 2003, 23:4371-4385.
13. Bilandzic M., Chu S., Farnworth P.G., Harrison C., Nicholls P., Wang Y., Escalona R.M., Fuller P.J., Findlay J.K., Stenvers K.L. Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. Mol. Endocrinol. 2009, 23:539-548.
14. Finger E.C., Turley R.S., Dong M., How T., Fields T.A., Blobe G.C. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 2008, 29:528-535.
15. Hempel N., How T., Dong M., Murphy S.K., Fields T.A., Blobe G.C. Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res. 2007, 67:5231-5238.
16. Sharifi N., Kawasaki B.T., Hurt E.M., Farrar W.L. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol. Ther. 2006, 5:901-906.
17. Turley R.S., Finger E.C., Hempel N., How T., Fields T.A., Blobe G.C. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 2007, 67:1090-1098.
18. Criswell T.L., Dumont N., Barnett J.V., Arteaga C.L. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res. 2008, 68:7304-7312.
19. Santander C., Brandan E. Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway. Cell. Signal. 2006, 18:1482-1491.
20. You H.J., Bruinsma M.W., How T., Ostrander J.H., Blobe G.C. The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis 2007, 28:2491-2500.
21. Kaname S., Ruoslahti E. Betaglycan has multiple binding sites for transforming growth factor-beta 1. Biochem. J. 1996, 315(Pt 3):815-820.
22. Sankar S., Mahooti-Brooks N., Centrella M., McCarthy T.L., Madri J.A. Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J. Biol. Chem. 1995, 270:13567-13572.
23. del Re E., Babitt J.L., Pirani A., Schneyer A.L., Lin H.Y. In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2. J. Biol. Chem. 2004, 279:22765-22772.
24. Rodriguez C., Chen F., Weinberg R.A., Lodish H.F. Cooperative binding of transforming growth factor (TGF)-beta 2 to the types I and II TGF-beta receptors. J. Biol. Chem. 1995, 270:15919-15922.
25. Rotzer D., Roth M., Lutz M., Lindemann D., Sebald W., Knaus P. Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor. EMBO J. 2001, 20:480-490.
26. Chapman S.C., Bernard D.J., Jelen J., Woodruff T.K. Properties of inhibin binding to betaglycan, InhBP/p120 and the activin type II receptors. Mol. Cell. Endocrinol. 2002, 196:79-93.
27. Esparza-Lopez J., Montiel J.L., Vilchis-Landeros M.M., Okadome T., Miyazono K., Lopez-Casillas F. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J. Biol. Chem. 2001, 276:14588-14596.
28. Kirkbride K.C., Townsend T.A., Bruinsma M.W., Barnett J.V., Blobe G.C. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J. Biol. Chem. 2008, 283:7628-7637.
29. Lewis K.A., Gray P.C., Blount A.L., MacConell L.A., Wiater E., Bilezikjian L.M., Vale W. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 2000, 404:411-414.
30. Makanji Y., Walton K.L., Wilce M.C., Chan K.L., Robertson D.M., Harrison C.A. Suppression of inhibin A biological activity by alterations in the binding site for betaglycan. J. Biol. Chem. 2008, 283:16743-16751.
31. Farnworth P.G., Stanton P.G., Wang Y., Escalona R., Findlay J.K., Ooi G.T. Inhibins differentially antagonize activin and bone morphogenetic protein action in a mouse adrenocortical cell line. Endocrinology 2006, 147:3462-3471.
32. Eickelberg O., Centrella M., Reiss M., Kashgarian M., Wells R.G. Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J. Biol. Chem. 2002, 277:823-829.
33. Wiater E., Vale W. Inhibin is an antagonist of bone morphogenetic protein signaling. J. Biol. Chem. 2003, 278:7934-7941.
34. Andres J.L., Stanley K., Cheifetz S., Massague J. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta. J. Cell Biol. 1989, 109:3137-3145.
35. Philip A., Hannah R., O'Connor-McCourt M. Ectodomain cleavage and shedding of the type III transforming growth factor-beta receptor in lung membranes effect of temperature, ligand binding and membrane solubilization. Eur. J. Biochem. 1999, 261:618-628.
36. Velasco-Loyden G., Arribas J., Lopez-Casillas F. The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J. Biol. Chem. 2004, 279:7721-7733.
37. Bandyopadhyay A., Lopez-Casillas F., Malik S.N., Montiel J.L., Mendoza V., Yang J., Sun L.Z. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res. 2002, 62:4690-4695.
38. Bandyopadhyay A., Wang L., Lopez-Casillas F., Mendoza V., Yeh I.T., Sun L. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate 2005, 63:81-90.
39. Bandyopadhyay A., Zhu Y., Malik S.N., Kreisberg J., Brattain M.G., Sprague E.A., Luo J., Lopez-Casillas F., Sun L.Z. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 2002, 21:3541-3551.
40. Juarez P., Vilchis-Landeros M.M., Ponce-Coria J., Mendoza V., Hernandez-Pando R., Bobadilla N.A., Lopez-Casillas F. Soluble betaglycan reduces renal damage progression in db/db mice. Am. J. Physiol. Renal Physiol. 2007, 292:F321-329.
41. Liu M., Suga M., Maclean A.A., St George J.A., Souza D.W., Keshavjee S. Soluble transforming growth factor-beta type III receptor gene transfection inhibits fibrous airway obliteration in a rat model of Bronchiolitis obliterans. Am. J. Respir. Crit. Care Med. 2002, 165:419-423.
42. Naumann U., Maass P., Gleske A.K., Aulwurm S., Weller M., Eisele G. Glioma gene therapy with soluble transforming growth factor-beta receptors II and III. Int. J. Oncol. 2008, 33:759-765.
43. Vilchis-Landeros M.M., Montiel J.L., Mendoza V., Mendoza-Hernandez G., Lopez-Casillas F. Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem. J. 2001, 355:215-222.
44. Mendoza V., Vilchis-Landeros M.M., Mendoza-Hernandez G., Huang T., Villarreal M.M., Hinck A.P., Lopez-Casillas F., Montiel J.L. Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor. Biochemistry 2009, 48:11755-11765.
45. Blobe G.C., Schiemann W.P., Pepin M.C., Beauchemin M., Moustakas A., Lodish H.F., O'Connor-McCourt M.D. Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling. J. Biol. Chem. 2001, 276:24627-24637.
46. Mythreye K., Blobe G.C. The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc. Natl Acad. Sci. USA 2009, 106:8221-8226.
47. You H.J., How T., Blobe G.C. The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. Carcinogenesis 2009, 30:1281-1287.
48. Blobe G.C., Liu X., Fang S.J., How T., Lodish H.F. A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. J. Biol. Chem. 2001, 276:39608-39617.
49. Chen W., Kirkbride K.C., How T., Nelson C.D., Mo J., Frederick J.P., Wang X.F., Lefkowitz R.J., Blobe G.C. Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science 2003, 301:1394-1397.
50. Finger E.C., Lee N.Y., You H.J., Blobe G.C. Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation. J. Biol. Chem. 2008, 283:34808-34818.
51. S. McLean, G.M. Di Guglielmo, TGF beta (transforming growth factor beta) receptor type III directs clathrin-mediated endocytosis of TGF beta receptor types I and II, Biochem J 429 (2010) 137-145.
52. Yu L., Hebert M.C., Zhang Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002, 21:3749-3759.
53. Chen L., Klass C., Woods A. Syndecan-2 regulates transforming growth factor-beta signaling. J. Biol. Chem. 2004, 279:15715-15718.
54. De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., Schroeter E.H., Schrijvers V., Wolfe M.S., Ray W.J., Goate A., Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999, 398:518-522.
55. E.B. Sorensen, S.D. Conner, gamma-secretase-dependent cleavage initiates notch signaling from the plasma membrane, Traffic 11 (2010) 1234-1245.
56. Foveau B., Ancot F., Leroy C., Petrelli A., Reiss K., Vingtdeux V., Giordano S., Fafeur V., Tulasne D. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol. Biol. Cell 2009, 20:2495-2507.
57. McElroy B., Powell J.C., McCarthy J.V. The insulin-like growth factor 1 (IGF-1) receptor is a substrate for gamma-secretase-mediated intramembrane proteolysis. Biochem. Biophys. Res. Commun. 2007, 358:1136-1141.
58. Sardi S.P., Murtie J., Koirala S., Patten B.A., Corfas G. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell 2006, 127:185-197.
59. Schulz J.G., Annaert W., Vandekerckhove J., Zimmermann P., De Strooper B., David G. Syndecan 3 intramembrane proteolysis is presenilin/gamma-secretase-dependent and modulates cytosolic signaling. J. Biol. Chem. 2003, 278:48651-48657.
60. Struhl G., Adachi A. Requirements for presenilin-dependent cleavage of Notch and other transmembrane proteins. Mol. Cell 2000, 6:625-636.
61. C. Ceni, R.P. Kommaddi, R. Thomas, E. Vereker, X. Liu, P.S. McPherson, B. Ritter, P.A. Barker, The p75NTR intracellular domain generated by neurotrophin-induced receptor cleavage potentiates Trk signaling, J Cell Sci 123 (2010) 2299-2307.
62. Fortini M.E. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat. Rev. Mol. Cell Biol. 2002, 3:673-684.
63. Hemming M.L., Elias J.E., Gygi S.P., Selkoe D.J. Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol. 2008, 6:e257.
64. Wrana J.L., Attisano L., Carcamo J., Zentella A., Doody J., Laiho M., Wang X.F., Massague J. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992, 71:1003-1014.
65. Andres J.L., Stanley K., Cheifetz S., Massague J. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta. J. Cell Biol. 1989, 109:3137-3145.
66. Dong M., How T., Kirkbride K.C., Gordon K.J., Lee J.D., Hempel N., Kelly P., Moeller B.J., Marks J.R., Blobe G.C. The type III TGF-beta receptor suppresses breast cancer progression. J. Clin. Invest. 2007, 117:206-217.
67. Cheifetz S., Bellon T., Cales C., Vera S., Bernabeu C., Massague J., Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J. Biol. Chem. 1992, 267:19027-19030.
68. Gougos A., Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J. Biol. Chem. 1990, 265:8361-8364.
69. Lux A., Gallione C.J., Marchuk D.A. Expression analysis of endoglin missense and truncation mutations: insights into protein structure and disease mechanisms. Hum. Mol. Genet. 2000, 9:745-755.
70. McAllister K.A., Grogg K.M., Johnson D.W., Gallione C.J., Baldwin M.A., Jackson C.E., Helmbold E.A., Markel D.S., McKinnon W.C., Murrell J., et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 1994, 8:345-351.
71. Li D.Y., Sorensen L.K., Brooke B.S., Urness L.D., Davis E.C., Taylor D.G., Boak B.B., Wendel D.P. Defective angiogenesis in mice lacking endoglin. Science 1999, 284:1534-1537.
72. Velasco S., Alvarez-Munoz P., Pericacho M., Dijke P.T., Bernabeu C., Lopez-Novoa J.M., Rodriguez-Barbero A. L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J. Cell Sci. 2008, 121:913-919.
73. Fernandez L.A., Sanz-Rodriguez F., Blanco F.J., Bernabeu C., Botella L.M. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway. Clin. Med. Res. 2006, 4:66-78.
74. Conley B.A., Koleva R., Smith J.D., Kacer D., Zhang D., Bernabeu C., Vary C.P. Endoglin controls cell migration and composition of focal adhesions: function of the cytosolic domain. J. Biol. Chem. 2004, 279:27440-27449.
75. Engel M.E., McDonnell M.A., Law B.K., Moses H.L. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J. Biol. Chem. 1999, 274:37413-37420.
76. Yue J., Mulder K.M. Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a Smad-dependent pathway. J. Biol. Chem. 2000, 275:35656.
77. Makeeva N., Roomans G.M., Myers J.W., Welsh N. Transforming growth factor-beta-activated protein kinase 1-binding protein (TAB)-1alpha, but not TAB1beta, mediates cytokine-induced p38 mitogen-activated protein kinase phosphorylation and cell death in insulin-producing cells. Endocrinology 2008, 149:302-309.